Sloss CM - Search Results

1

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.

Kearns JD, Bukhalid R, Sevecka M, Tan G, Gerami-Moayed N, Werner SL, Kohli N, Burenkova O, Sloss CM, King AM, Fitzgerald JB, Nielsen UB, Wolf BB. Kearns JD, et al. Among authors: sloss cm. Mol Cancer Ther. 2015 Jul;14(7):1625-36. doi: 10.1158/1535-7163.MCT-14-0772. Epub 2015 Apr 24. Mol Cancer Ther. 2015. PMID: 25911688

2

IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.

Kovtun Y, Noordhuis P, Whiteman KR, Watkins K, Jones GE, Harvey L, Lai KC, Portwood S, Adams S, Sloss CM, Schuurhuis GJ, Ossenkoppele G, Wang ES, Pinkas J. Kovtun Y, et al. Among authors: sloss cm. Mol Cancer Ther. 2018 Jun;17(6):1271-1279. doi: 10.1158/1535-7163.MCT-17-1077. Epub 2018 Mar 27. Mol Cancer Ther. 2018. PMID: 29588393

3

Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.

Sloss CM, Wang F, Liu R, Xia L, Houston M, Ljungman D, Palladino MA, Cusack JC Jr. Sloss CM, et al. Clin Cancer Res. 2008 Aug 15;14(16):5116-23. doi: 10.1158/1078-0432.CCR-07-4506. Clin Cancer Res. 2008. PMID: 18698029 Free PMC article.

4

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. Boni A, et al. Among authors: sloss cm. Cancer Res. 2010 Jul 1;70(13):5213-9. doi: 10.1158/0008-5472.CAN-10-0118. Epub 2010 Jun 15. Cancer Res. 2010. PMID: 20551059

5

Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells.

Wang F, Sloss C, Zhang X, Lee SW, Cusack JC. Wang F, et al. Cancer Res. 2007 Sep 15;67(18):8486-93. doi: 10.1158/0008-5472.CAN-07-0498. Cancer Res. 2007. PMID: 17875687

6

Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells.

Sloss CM, Wang F, Palladino MA, Cusack JC Jr. Sloss CM, et al. Oncogene. 2010 May 27;29(21):3146-52. doi: 10.1038/onc.2010.52. Epub 2010 Mar 8. Oncogene. 2010. PMID: 20208558 Free PMC article.

7

The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models.

Hicks SW, Lai KC, Gavrilescu LC, Yi Y, Sikka S, Shah P, Kelly ME, Lee J, Lanieri L, Ponte JF, Sloss CM, Romanelli A. Hicks SW, et al. Among authors: sloss cm. Neoplasia. 2017 Sep;19(9):661-671. doi: 10.1016/j.neo.2017.06.001. Epub 2017 Jul 25. Neoplasia. 2017. PMID: 28753442 Free PMC article.

8

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.

Hicks SW, Tarantelli C, Wilhem A, Gaudio E, Li M, Arribas AJ, Spriano F, Bordone R, Cascione L, Lai KC, Qiu Q, Taborelli M, Rossi D, Stussi G, Zucca E, Stathis A, Sloss CM, Bertoni F. Hicks SW, et al. Among authors: sloss cm. Haematologica. 2019 Aug;104(8):1633-1639. doi: 10.3324/haematol.2018.211011. Epub 2019 Feb 7. Haematologica. 2019. PMID: 30733273 Free PMC article.

9

[No title available]

[No authors listed] [No authors listed] PMID: 36163801

10

Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance.

Wang F, Liu R, Lee SW, Sloss CM, Couget J, Cusack JC. Wang F, et al. Among authors: sloss cm. Oncogene. 2007 Mar 29;26(14):2006-16. doi: 10.1038/sj.onc.1209999. Epub 2006 Sep 25. Oncogene. 2007. PMID: 17001310

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page